RecruitingPhase 4

Effect of Itopride on Semaglutide Gastroparesis

Does Itopride Improve Semaglutide Induced Gastroparesis Ultrasound Before Anesthesia? Randomized Controlled Trial

Lead sponsor

Ain Shams University

Asset

Semaglutide

GLP-1 agonist

Listed sites

Recruiting sites

Estimated enrollment

Study population

Gastrointestinal (gastroparesis / short bowel / pancreatitis), Perioperative / gastric aspiration risk, Type 2 diabetes

Eligibility highlights

•BMI 20-30•Female

Primary endpoint

•Residual gastric contents

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07254715

Org study IDFMASU R263/2025

Timeline

Milestones

Study first posted2025-11-28actual

Last update posted2025-11-28actual

Study start2025-12estimated (month precision)

Primary completion2026-04estimated (month precision)

Study completion2026-04estimated (month precision)

Assets

Investigational agents

Semaglutide

Who this study enrolls

Gastrointestinal (gastroparesis / short bowel / pancreatitis)Perioperative / gastric aspiration riskType 2 diabetes

Who can enroll

Minimum age40 Years

Maximum age60 Years

SexFemale

Healthy volunteersNot accepted

Inclusion criteria

•American Society of Anesthesiologists grade I- III.

•Age: 40-60 years.

•BMI: 20-30 kg/m2.

•Diabetic patients on semaglutide (0.5-1mg) SC weekly.

•Undergoing elective hysterectomy.

Exclusion criteria

•Declining to give written informed consent.

•history of upper abdominal surgery or the presence of hiatal hernia.

•Other medications inducing gastroparesis (opioids, proton pump inhibitors, tricyclic antidepressants, calcium channel blockers, antipsychotic medications, and lithium).

•History of allergy to Itopride.

•History of cardiac arrhythmia or abnormal ECG.

•Neurologic diseases (including Parkinson's disease and multiple sclerosis)

•Hepatic or renal failure.

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

Incidence of vomiting during anesthesia

Time frame:during anesthesia

Vomiting

event count, event

Other clinical outcomes

2 endpoints

Primary/protocol endpoint

Residual gastric contents

Time frame:on day 7

threshold achievement, event

Secondary/protocol endpoint/low confidence

Residual gastric contents on day 3 and day 5.

Time frame:on day 3 and day 5

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.